We are live on ! Find out more
TCRR

TCR2 Therapeutics Inc. Common Stock
TCRR

Delisted

TCRR was delisted on the 31st of May, 2023.

Back to rankings

64 hedge funds and large institutions have $234M invested in TCR2 Therapeutics Inc. Common Stock in 2020 Q2 according to their latest regulatory filings, with 18 funds opening new positions, 26 increasing their positions, 13 reducing their positions, and 4 closing their positions.

New
Increased
Maintained
Reduced
Closed

350% more first-time investments, than exits

New positions opened: 18 | Existing positions closed: 4

111% more capital invested

Capital invested by funds: $111M → $234M (+$123M)

100% more repeat investments, than reductions

Existing positions increased: 26 | Existing positions reduced: 13

28% more funds holding

Funds holding: 50 → 64 (+14)

0% more funds holding in top 10

Funds holding in top 10: 2 → 2 (0)

Holders
64
Holders Change
+14
Holders Change %
+28%
% of All Funds
1.31%
Holding in Top 10
2
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.04%
New
18
Increased
26
Reduced
13
Closed
4
Calls
$633K
Puts
–
Net Calls
+$633K
Net Calls Change
+$742K

Top Buyers

Rank Fund Capital Flow
1
BlackRock
BlackRock
New York
+$2.31M
2
Morgan Stanley
Morgan Stanley
New York
+$1.54M
3
Northern Trust
Northern Trust
Illinois
+$1.17M
4
GPCM
Granite Point Capital Management
Massachusetts
+$1.15M
5
State Street
State Street
Massachusetts
+$640K

Top Sellers

Rank Fund Capital Flow
1
Victory Capital Management
Victory Capital Management
Texas
-$980K
2
AG
Artal Group
Luxembourg
-$577K
3
DCM
DAFNA Capital Management
California
-$376K
4
Millennium Management
Millennium Management
New York
-$360K
5
Ameriprise
Ameriprise
Minnesota
-$295K
Name Holding Trade Value Shares
Change 		Change in
Stake
Citigroup
51
Citigroup
New York
$47K -$35K -3,032 -50%
Russell Investments Group
52
Russell Investments Group
United Kingdom
$39K +$29.9K +2,588 New
TRCT
53
Tower Research Capital (TRC)
New York
$38K +$6.28K +544 +28%
Legal & General Group
54
Legal & General Group
United Kingdom
$32K +$6.21K +538 +34%
Bank of Montreal
55
Bank of Montreal
Ontario, Canada
$21K +$15K +1,300 New
CG
56
Cutler Group
California
$16K +$12.7K +1,100 New
AIP
57
Ameritas Investment Partners
Nebraska
$15K – – –
US Bancorp
58
US Bancorp
Minnesota
$11K – – –
BNP Paribas Financial Markets
59
BNP Paribas Financial Markets
France
$10K -$34.2K -2,965 -82%
Simplex Trading
60
Simplex Trading
Illinois
$5K +$1.9K +165 +75%
MF
61
Manchester Financial
California
$3K – – –
TFA
62
Toth Financial Advisory
Virginia
$2K – – –
BCA
63
Berman Capital Advisors
Georgia
$1K +$807 +70 New
SCM
64
Soleus Capital Management
Connecticut
– -$237K -30,624 Closed
Citadel Advisors
65
Citadel Advisors
Florida
– -$132K -17,077 Closed
Acadian Asset Management
66
Acadian Asset Management
Massachusetts
– -$14K -1,766 Closed
FDCDDQ
67
Federation des caisses Desjardins du Quebec
Quebec, Canada
– -$2.32K -300 Closed
Royal Bank of Canada
68
Royal Bank of Canada
Ontario, Canada
– -$2.91K -252 -91%
1 2
3

TCRR Hedge Fund Activity: Q2 2020 in Review

64 of the 4,878 institutional investors tracked by Wall St. Rank reported a position in TCR2 Therapeutics Inc. Common Stock (TCRR) for Q2 2020, worth a combined $234M — up 111% from $111M a quarter earlier.

Buyers outnumbered sellers: 18 funds opened new TCRR positions and 4 closed out — a net gain of 14 holders — while 26 added to existing stakes and 13 trimmed.

The largest buyer was BlackRock, adding an estimated $2.31M. The largest seller was Victory Capital Management, cutting an estimated $980K.

  • 64 institutional investors held TCR2 Therapeutics Inc. Common Stock (TCRR) as of Q2 2020, up from 50 in Q1 2020.
  • Funds reported $234M of TCR2 Therapeutics Inc. Common Stock stock for Q2 2020, up 111% quarter-over-quarter.
  • 18 funds opened new TCR2 Therapeutics Inc. Common Stock positions in Q2 2020 and 4 closed out, a net change of +14 holders.
  • The largest TCR2 Therapeutics Inc. Common Stock buyer in Q2 2020 was BlackRock, an estimated $2.31M added.
  • The largest TCR2 Therapeutics Inc. Common Stock seller in Q2 2020 was Victory Capital Management, an estimated $980K sold.

Based on aggregated 13F filings for Q2 2020.